Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
Diana Wong, Wendy J. van Zuylen, Talia Novos, Sophie L. Stocker, Stephanie E. Reuter, Jane Au, Charles S. P. Foster, Richard O. Day, Andrea R. Horvath, Zoltán Endre, William D. Rawlinson
Abstract
This study examined the pharmacokinetics and viral genomic data from a prospective cohort of kidney transplant recipients undergoing valganciclovir prophylaxis for cytomegalovirus (CMV) prevention. We showed for the first time using high-throughput sequencing the detection of ganciclovir resistance mutations in breakthrough CMV infection during subtherapeutic plasma ganciclovir as indicated by the pharmacokinetic parameter daily area under the curve (AUC 24 ).
Topics & Concepts
ValganciclovirGanciclovirMedicinePharmacokineticsDosingCytomegalovirusKidney transplantationHuman cytomegalovirusInternal medicineTransplantationProspective cohort studyPopulationRenal functionGastroenterologyPharmacologyImmunologyHerpesviridaeVirusViral diseaseEnvironmental healthCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsPneumocystis jirovecii pneumonia detection and treatment